They also relate to the demonstration that a combination of anti-CD137 mAb with cisplatin induced 60% regression of mouse CT-26 colon carcinoma [38], although we did not observe any beneficial effect against the ID8 tumor unless the anti-CD137 mAb was combined with an anti-PD1 mAb. This evidence concerns the gene TNFRSF9 and colon carcinoma.